ADAMTS-13 activity in the presence of elevated von Willebrand factor levels as a novel mechanism of residual platelet reactivity in high risk coronary patients on antiplatelet treatment

Thrombosis Research

Volumn 123, Issue 1, 2008, Pages 130-136

  Marcucci, Rossella ^a   Cesari, Francesca ^a   Cinotti, Sandro ^b   Paniccia, Rita ^a   Gensini, Gian Franco ^c   Abbate, Rosanna ^a   Gori, Anna Maria ^a  

^a Center for the Study at Molecular and Clinical Level of Chronic   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

ADAMTS 13; Antiaggregant therapy; Aspirin resistance; Residual platelet reactivity; von Willebrand Factor

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; HEPARIN; INTERLEUKIN 6; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD PLATELETS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; VON WILLEBRAND FACTOR;

EID: 54149097918     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.05.017     Document Type: Article

References (34)

1. Chen W.H., Lee P.Y., Ng W., Tse H.F., and Lau C.P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary interventions despite clopidogrel pre-treatment. J Am Coll Cardiol 43 (2004) 1122-1126
2. Matetzky S., Shenkman B., Guetta V., Shecter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associate with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
3. Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., et al. Platelet reactivity in patients and recurrent events post-stenting. Results of the PREPARE POST-STENTING study. J Am Coll Cardiol 46 (2005) 1820-1826
4. Marcucci R., Paniccia R., Antonucci E., Gori A.M., Fedi S., Giglioli C., et al. Sefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 98 (2006) 1156-1159
5. Cuisset T., Frere C., Quilici J., Barbou F., Morange P.E., Hovasse T., et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4 3 (2006) 542-549
6. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., et al. Impact of platelet reactivity following clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
7. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., and Gurbel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 49 (2007) 657-666
8. Wang T.H., Bhatt D.L., and Topol E. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27 (2006) 647-654
9. Dong J.F. Cleavage of ultralarge von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 3 (2005) 2536-2544
10. Vischer U.M. Von Willebrand factor, endothelial dysfunction and cardiovascular disease. J Thromb Haemost 4 (2006) 1186-1193
11. Giusti B., Gori A.M., Marcucci R., Sestini I., Saracini C., Paniccia R., et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis 196 (2008) 341-348
12. Mannini L., Marcucci R., Paniccia R., Antonucci E., Giglioli C., Valente S., et al. Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients. Clin Hemorheol Microcirc 35 (2006) 175-181
13. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
14. Marcucci R., Gori A.M., Paniccia R., Giglioli C., Buonamici P., Antoniucci D., et al. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis 195 (2007) e217-e223
15. Geisler T., Langer H., Wydymus M., Gohring K., Zurn C., Bigalke B., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27 (2006) 2420-2425
16. Chobainian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.R.J.L., et al. The Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 289 (2003) 2560-2571
17. Third Report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adult (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143--3121
18. Reports of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 (2003) S5-S20
19. Siekmann J., Turecek P.L., and Schwarz H.P. The determination of Von Willebrand factor activity by collagen binding assay. Haemophilia 4 (1998) 15-24
20. Budde U., Drewke E., Mainusch K., and Schneppenheim R. Laboratory diagnosis of congenital von Willebrand disease. Semin Thromb Hemost 28 (2002) 173-190
21. Reiter R.A., Varadi K., Turecek P.L., Jilma B., and Knobl P. Changes in ADAMTS-13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost 93 (2005) 554-558
22. Arya M., Anvari B., Romo G.M., Criz M.A., Dong J.F., McIntire L.V., et al. Unltralarge multimers of von Willebrand factor form spontaneous high-strenght bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 99 (2002) 3971-3977
23. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol 72 (1996) 341-348
24. Mannucci P.M., Capoferri C., and Canciani M.T. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol 126 (2004) 213-218
25. Bernardo A., Ball C., Nolasco L., Moake J.F., and Dong J. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 104 (2004) 100-106
26. Crawley J.T., Lam J.K., Rance J.B., Mollica L.R., O'Donnell J.S., and Lane D.A. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 105 (2005) 1085-1093
27. Zairis M.N., Adamopoulou E.N., Manousakis S.J., Lyras A.G., Bibis G.P., Ampartzidou O.S., et al. for the Biomarkers of Inflammation and Outcome in Acute Coronary Syndromes (BIAS) Investigators. The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis (Sep 7 2006)
28. Biasucci L.M., Liuzzo G., Fantuzzi G., Caligiuri G., Rebuzzi A.G., Ginnetti F., et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99 16 (Apr 27 1999) 2079-2084
29. Neri Serneri G.G., Gensini G.F., Abbate R., Laureano P., and Parodi O. Is raised plasma fibrinopeptide A a marker of acute coronary insufficiency?. Lancet 2 (1980) 982-983
30. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 25 (Jun 28 2005) 3481-3488
31. Lam J.K., Chion C.K., Zanardelli S., Lane D.A., and Crawely J.T. Further characterization of ADAMTS-13 inactivation by thrombin. J Thromb Haemost 5 (2007) 1010-1018
32. Ruggeri Z.M., and Mendolicchio G.L. Adhesion mechanisms in platelet function. Circ Res 100 (2007) 1673-1685
33. Furman M.I., Barnard M.R., Krueger L.A., Fox M.L., Shilale E.A., Lessard D.M., et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 38 4 (2001 Oct) 1002-1006
34. Crescente M., Di Castelnuovo A., Iacoviello L., Vermylen J., Cerletti C., and de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)- 100. Thromb Haemost 99 (2008) 14-26